Rheumatoid Arthritis

Percentage of Newly Diagnosed Patients With Rheumatoid Arthritis Starting Biologic DMARDs Who Had Tuberculosis Testing (2015-2019)

Percentage of Newly Diagnosed Patients With Rheumatoid Arthritis Starting Biologic DMARDs Who Had Tuberculosis Testing (N = 864)

2015-2019

  1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 Jan;68(1):1-25.

The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis recommends tuberculosis (TB) screening before using biologic agents to identify latent TB infection (LTBI)¹. The ACR recommends the tuberculin skin test or interferon-γ release assays as the initial test in all rheumatoid arthritis patients starting biologic agents, regardless of risk factors for LTBI. In 2015, 91.3% (167 of 183), in 2016, 89.8% (176 of 196), in 2017, 92.8% (154 of 166), in 2018, 87.0% (160 of 184), and in 2019, 85.2% (115 of 135) of patients had TB testing. Over 75% of patients without a TB test had TB testing outside of the Cleveland Clinic.